ES2185695T3 - Terapia genica dirigida. - Google Patents

Terapia genica dirigida.

Info

Publication number
ES2185695T3
ES2185695T3 ES95908333T ES95908333T ES2185695T3 ES 2185695 T3 ES2185695 T3 ES 2185695T3 ES 95908333 T ES95908333 T ES 95908333T ES 95908333 T ES95908333 T ES 95908333T ES 2185695 T3 ES2185695 T3 ES 2185695T3
Authority
ES
Spain
Prior art keywords
gene therapy
directed gene
hypoxia
pro
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95908333T
Other languages
English (en)
Inventor
Peter John Ratcliffe
John David Firth
Adrian Llewllyn Harris
Christopher William Pugh
Ian James Stratford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Application granted granted Critical
Publication of ES2185695T3 publication Critical patent/ES2185695T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1217—Phosphotransferases with a carboxyl group as acceptor (2.7.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LOS CONSTRUCTORES DE ACIDO NUCLEICO QUE COMPRENDEN AL MENOS UN GEN QUE CODIFICA UNA ESPECIE QUE TIENE ACTIVIDAD CONTRA LA ENFERMEDAD COMO UN SISTEMA DE ACTIVACION DE PROFARMACOS OPERATIVAMENTE UNIDO A UNA SECUENCIA DE CONTROL DE LA EXPRESION HIPOXICAMENTE INDUCIBLE, Y SU USO PARA EL TRATAMIENTO EN EL CASO DE LAS ENFERMEDADES DONDE ESTE PRESENTE LA HIPOXIA.
ES95908333T 1994-02-15 1995-02-15 Terapia genica dirigida. Expired - Lifetime ES2185695T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9402857A GB9402857D0 (en) 1994-02-15 1994-02-15 Targeting gene therapy

Publications (1)

Publication Number Publication Date
ES2185695T3 true ES2185695T3 (es) 2003-05-01

Family

ID=10750384

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95908333T Expired - Lifetime ES2185695T3 (es) 1994-02-15 1995-02-15 Terapia genica dirigida.

Country Status (9)

Country Link
US (2) US5942434A (es)
EP (2) EP0745131B1 (es)
JP (2) JP3924007B2 (es)
AT (1) ATE230439T1 (es)
DE (1) DE69529276T2 (es)
DK (1) DK0745131T3 (es)
ES (1) ES2185695T3 (es)
GB (1) GB9402857D0 (es)
WO (1) WO1995021927A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402857D0 (en) * 1994-02-15 1994-04-06 Isis Innovation Targeting gene therapy
DE19617851A1 (de) 1996-05-03 1997-11-13 Hoechst Ag Nukleinsäurekonstrukte mit Genen kodierend für Transportsignale
DE19639103A1 (de) 1996-09-24 1998-03-26 Hoechst Ag Nukleinsäurekonstrukte mit Hybridpromotoren für gentherapeutische Maßnahmen
EP0935471B1 (en) * 1996-10-09 2005-03-09 Oxford Biomedica (UK) Limited Mononuclear phagocytes in therapeutic drug delivery
AU770427B2 (en) * 1996-10-09 2004-02-19 Oxford Biomedica (Uk) Limited Mononuclear phagocytes in therapeutic drug delivery
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
KR20010052076A (ko) * 1997-09-23 2001-06-25 찰스 굿맨 허혈 조건에서 헤마토포이에틱 스템 세포의 유전자 발현
EP1100548A2 (en) * 1998-07-28 2001-05-23 Advanced Tissue Sciences, Inc. Genetically engineered cells and tissues
US20040234505A1 (en) * 1998-09-23 2004-11-25 Stuart Naylor Polynucleotide constructs and uses thereof
JP2002526083A (ja) * 1998-09-23 2002-08-20 オックスフォード バイオメディカ（ユーケイ）リミテッド ポリヌクレオチド構築物およびその使用
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
US6893867B1 (en) 1999-12-23 2005-05-17 Keith A. Webster Molecular switch for regulating mammalian gene expression
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
US7910549B2 (en) 2001-12-13 2011-03-22 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
WO2003064664A1 (en) * 2002-01-31 2003-08-07 Oxford Biomedica (Uk) Limited Physiologically regulated erythropoietin- exprressing vector for the treatment of anaemia
GB0202252D0 (en) * 2002-01-31 2002-03-20 Oxford Biomedica Ltd Anemia
US7550424B2 (en) 2002-11-26 2009-06-23 Institute Of Virology Slovak Academy Of Sciences CA IX-specific inhibitors
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US20050048045A1 (en) * 2003-07-02 2005-03-03 Board Of Regents, The University Of Texas System Regulation of urokinase receptor expression by phosphoglycerate kinase
US20060074182A1 (en) * 2004-09-30 2006-04-06 Depuy Products, Inc. Hydrogel composition and methods for making the same
AU2006254897A1 (en) * 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
MX2007016160A (es) 2005-06-15 2008-03-07 Fibrogen Inc Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.
WO2007097929A1 (en) * 2006-02-16 2007-08-30 Fibrogen, Inc. Compounds and methods for treatment of stroke
KR100949975B1 (ko) * 2006-03-30 2010-03-29 엘지전자 주식회사 비디오 신호를 디코딩/인코딩하기 위한 방법 및 장치
EP2150276B1 (en) 2007-05-03 2014-05-21 Agency For Science, Technology And Research Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
US7919006B2 (en) * 2007-10-31 2011-04-05 Freescale Semiconductor, Inc. Method of anti-stiction dimple formation under MEMS
US20100125265A1 (en) * 2008-11-20 2010-05-20 Medtronic Vascular, Inc. Cell Delivery System to Induce Cell Growth and Angiogenesis
US20250290916A1 (en) 2022-05-06 2025-09-18 Antibody Analytics Limited Chemically Induced Proximity Systems

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645243B2 (en) * 1988-03-18 1994-01-13 General Hospital Corporation, The Human heat shock factor
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP0650370A4 (en) * 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
GB9323008D0 (en) * 1993-11-05 1994-01-05 Connors Thomas Improvements relating to cancer therapy
AU1095595A (en) * 1993-11-10 1995-05-29 Amgen, Inc. Gene therapy vector for the treatment of low or defective red blood cell production
GB9402857D0 (en) * 1994-02-15 1994-04-06 Isis Innovation Targeting gene therapy

Also Published As

Publication number Publication date
DK0745131T3 (da) 2003-03-31
EP1136561A2 (en) 2001-09-26
JPH09508531A (ja) 1997-09-02
GB9402857D0 (en) 1994-04-06
WO1995021927A3 (en) 1995-09-08
ATE230439T1 (de) 2003-01-15
JP2006314331A (ja) 2006-11-24
WO1995021927A2 (en) 1995-08-17
US6265390B1 (en) 2001-07-24
JP3924007B2 (ja) 2007-06-06
US5942434A (en) 1999-08-24
DE69529276D1 (de) 2003-02-06
EP1136561A3 (en) 2004-03-31
EP0745131A1 (en) 1996-12-04
EP0745131B1 (en) 2003-01-02
DE69529276T2 (de) 2009-09-17

Similar Documents

Publication Publication Date Title
ES2185695T3 (es) Terapia genica dirigida.
DE69022290D1 (de) Lebende Impfstoffe.
BG44877A3 (bg) Метод за експресия на ген,кодиращ човешки имунен интерферон
DE69331467D1 (de) Oligonukleotide modulation von protein kinase c
ATE298793T1 (de) Transgene tiermodelle für herz-hypertrophie und deren verwendungen
ATE290077T1 (de) Regulierte gene und ihre verwendungen
NO904023D0 (no) Blanding som induserer binding.
DK166763C (da) Immunoglobulin-g-holdig fraktion
BR9204191A (pt) Composicao de isca e processo para controlar populacoes de besouro diabroticine,e isca
ATE210466T1 (de) Methoden zur behandlung von atemwegserkrankungen
FI940463L (fi) Mikro-organismi kasvitautien biologiseen torjuntaan
AU2001245319A1 (en) Methods of treating diseases with activated protein c
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
FI944557L (fi) Mikro-organismi kasvitautien biologiseen torjuntaan
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
HUP9800247A2 (hu) Humán endoglin gén promóter és annak alkalmazása
EP0527941A4 (es)
FI950649L (fi) Substituoidut sykloheksanoliesterit, niiden käyttö sairauksien hoitamiseksi ja farmaseuttiset valmisteet
DE59611293D1 (de) Protein mit dnase-aktivität
DE3850933D1 (de) Anticoagulatorisches Protein PP4-X, seine Herstellung und Verwendung.
IT1234390B (it) Prodotti microbici ottenuti mediante la coltivazione do achromobacter stenohalis, per combattere malattie virali
DE69813573D1 (de) Verbesserungen der oder in bezug auf die regulierung der t-zellaktivation
IT8785642A0 (it) Miscela aria ammoniaca. impianto per il trattamento dei sottoprodotti agricoli mediante